A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

July 11, 2024

Study Completion Date

July 11, 2024

Conditions

Overweight

Interventions

DRUG

LY3437943

Administered SC.

DRUG

Ethinyl Estradiol

Administered orally

DRUG

Drospirenone

Administered orally

Trial Locations (2)

Qps-Mra, Llc, South Miami

ICON Early Phase Services, San Antonio

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06039826 - A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese | Biotech Hunter | Biotech Hunter